Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.27 EPS, surpassing estimates of $1.12 by $0.15. The company had revenue of $327.32 million, exceeding the expected $311.61 million, although revenue declined by 5.3% year-over-year. Haemonetics updated its FY 2026 guidance to 4.800-5.00 EPS. The stock traded up to $68.70, with a market cap of $3.31 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $78.50. Institutional investors hold 99.67% of the company's stock.
Haemonetics (NYSE:HAE - Get Free Report) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.15, Zacks reports. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter last year, the company earned $1.12 earnings per share. The firm's revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics updated its FY 2026 guidance to 4.800-5.00 EPS.
Haemonetics Stock Performance
NYSE:HAE traded up $1.59 during midday trading on Friday, hitting $68.70. The company's stock had a trading volume of 3,209,056 shares, compared to its average volume of 849,000. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The firm has a market cap of $3.31 billion, a P/E ratio of 21.01, a P/E/G ratio of 0.91 and a beta of 0.43. The firm's 50 day moving average is $51.53 and its 200-day moving average is $62.12.
Analyst Upgrades and Downgrades
Several analysts have commented on HAE shares. Weiss Ratings lowered shares of Haemonetics from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Saturday, October 25th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. BTIG Research raised their target price on shares of Haemonetics from $85.00 to $88.00 and gave the company a "buy" rating in a research note on Thursday. Barrington Research upped their price target on Haemonetics from $86.00 to $90.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, Raymond James Financial downgraded Haemonetics from a "strong-buy" rating to an "outperform" rating and dropped their target price for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $78.50.
View Our Latest Report on HAE
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Sivia Capital Partners LLC purchased a new position in shares of Haemonetics during the 2nd quarter valued at about $234,000. Caxton Associates LLP acquired a new stake in Haemonetics during the first quarter worth about $216,000. United Services Automobile Association purchased a new position in Haemonetics during the first quarter valued at approximately $212,000. Strs Ohio acquired a new position in Haemonetics in the first quarter valued at approximately $140,000. Finally, EverSource Wealth Advisors LLC boosted its position in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.
About Haemonetics
(Get Free Report)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
- Five stocks we like better than Haemonetics
- Investing in Commodities: What Are They? How to Invest in Them
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- When to Sell a Stock for Profit or Loss
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- 3 Warren Buffett Stocks to Buy Now
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Haemonetics Right Now?
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
